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Summary
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease defined clin-
ically by multiple, painful inflammatory lesions occurring predominantly in flexu-
ral sites. Onset is typically soon after puberty; however, it remains unknown
whether the menopause induces remission. In North American and European
patients with HS the female-to-male ratio is approximately 3 : 1 but the ratio is
1 : 2 in South Korean patients. It may be that some elements of HS epidemiology
cannot be generalized across all populations. Elements of HS epidemiology in the
USA and Europe are well established, including strong associations with obesity
and smoking, which may increase disease severity. There are associations between
HS and other cardiovascular disease (CVD) risk factors, including type 2 diabetes
and metabolic syndrome. People with HS have double the risk of death from
CVD compared with those without HS and 15 times the risk compared with
patients with psoriasis. Depression and anxiety are associated with HS and com-
pleted suicide rates in those with HS are more than double the rates in controls.
Associations exist between HS and other chronic inflammatory conditions, partic-
ularly inflammatory bowel disease and inflammatory arthritis. Case–control stud-
ies demonstrate associations with pilonidal sinus, polycystic ovary syndrome,
Down syndrome, obstructive sleep apnoea and pyoderma gangrenosum. Popula-
tion-based studies using routinely collected healthcare data from the USA estimate
a prevalence of 01%, suggesting HS is relatively uncommon. European studies
include undiagnosed patients and typically estimate prevalence of 1% or more,
suggesting a common condition. Resolving the controversy surrounding a greater
than 10-fold difference in HS prevalence estimates remains a high priority.
What is already known about this topic?
• Hidradenitis suppurativa (HS) prevalence figures vary more than 80-fold, from
0.05% to 4.1%.
• In North America and Europe, HS is most prevalent in adult women of working
age.
• HS is linked to smoking and obesity.
What does this study add?
• Wide variation in HS prevalence estimates is probably due to differing data
sources, different levels of recognition of HS and variable inclusion of undiagnosed
cases.
• HS is associated with other chronic inflammatory diseases, cardiovascular disease
(CVD) and depression.
• Mortality rates from CVD are more than 50% higher in HS than in psoriasis and
there is an increased risk of completed suicide compared with controls.
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Hidradenitis suppurativa (HS) is a chronic skin disease charac-
terized by painful inflammatory nodules and abscesses in flex-
ural sites that exude pus and often lead to scarring.1
Investigation of the epidemiology of HS is challenging because
the diagnosis is often delayed or never formally established.
Average diagnostic delay for HS is 72 years, compared with
16 years for psoriasis.2
Case definition
Determination of HS prevalence and incidence requires a stan-
dard disease definition. The definition of HS is clinical, with no
diagnostic test. The original disease definition was developed by
consensus at two international HS meetings in 2006 and 2009,
resulting in the following description: ‘a chronic, inflammatory,
recurrent, debilitating, skin follicular disease that usually pre-
sents after puberty with painful deep seated, inflamed lesions in
the apocrine gland-bearing areas of the body, most commonly,
the axillary, inguinal and anogenital regions’.3,4 There are three
key elements to the diagnosis: (i) characteristic inflamed skin
lesions; (ii) predominantly flexural sites, in particular the axillae
and groin; and (iii) chronicity. The gold-standard case defini-
tion is from history-taking and in-person examination by a clin-
ician who is experienced in HS care, including features such as
characteristic scarring and skin tunnel (also known as sinus tract
or skin fistula) formation, which may be present.
Prevalence
The prevalence of HS remains a highly controversial subject,
with figures for Europe and North America ranging from
005% to 41%, an 82-fold difference.5,6 How can estimates
of similar populations vary so widely? The answer may relate
to the diversity of methodologies and data sources utilized.
Table 1 lists the different methods and provides examples of
the prevalence figures obtained. The highest figure of 41% is
based on an examination of 507 Danish young adults, mean
age approximately 27 years old, undergoing screening for sex-
ually transmitted diseases (STDs).6 There were 20 cases of HS,
in six men and 14 women. The study used the gold-standard
case definition of in-person examination by a dermatologist.
The relatively high prevalence figure may in part relate to the
age range of participants, who were mainly in their third and
fourth decades and could also have been influenced by case
ascertainment bias in terms of STD clinic attendees being con-
cerned about genital HS lesions.
The lowest HS prevalence figure used insurance data from
the USA to estimate period prevalence in 20075 There are
several reasons why the figure is likely to be an underestimate:
(i) insurance data misses uninsured patients who probably
have a higher prevalence of HS because it is more common in
lower socioeconomic groups;7 (ii) only diagnosed patients
and those receiving a HS-specific procedure were included,
missing undiagnosed patients estimated to be at least one-third
of the total;8,9 (iii) case ascertainment relies on clinical recog-
nition of HS, which may vary between locations and over
time; and (iv) population-based data relies on accurate diag-
nostic coding.
Prevalence in studies from the USA tends to be lower than
in European studies. Could the difference be due to variation
in ethnicity and genetics between the populations of the USA
and Europe? Prevalence in African-Americans was three times
higher, rather than lower, than in white individuals,10 which
counts against this argument. It is more likely that the differ-
ence relates to the differing data sources and methodologies
used in studies of US and European populations.
Epidemiology data for Asian populations are more limited.
A population-based cross-sectional study of the South Korean
National Health Insurance database using International Classifi-
cation of Diseases, 10th revision codes found a 10-year period
prevalence of 006%.11 Prevalence in Australia, using a vali-
dated screening questionnaire, was 067% [95% confidence
interval (CI) 053–084%].12 Data for Africa are currently lim-
ited; however, a recent questionnaire study conducted in
Ghana found a prevalence of 08%.13
Incidence
In keeping with the wide variation in prevalence estimates
between studies, incidence figures from population-based
studies also show wide variation. Annual incidence in the USA
was 114 (95% CI 111–118) cases per 100 000 popula-
tion,14 while in the UK it was 283.8 It has been hypothesized
that HS incidence rates may be increasing due to increasing
recognition of the condition. In support of this hypothesis,
population-based data from the USA show that HS incidence
in 2015–16 was one-third higher than the average annual
incidence during the decade from 2006 to 201614 In con-
trast, the UK study found a relatively static incidence rate.8
Demographics
In European and North American populations, HS has a clear
female preponderance, with a female-to-male ratio of approxi-
mately 3 : 18,10,15 The reverse was found in South Korea,
with a female-to-male ratio of approximately 1 : 211,16 Preva-
lence is highest in the fourth and fifth decades of life.8,10,15
Onset of HS typically occurs in young adulthood, with a new
diagnosis being most common in people aged 18–29 years of
age in the USA.14 Factoring in a typical diagnostic delay of
7 years,2 this fits with the hypothesis that onset occurs at or
soon after puberty in many patients. Reports of prepubertal
HS are limited to small case series, reflecting its relative rar-
ity.17 Association is reported between HS and lower socioeco-
nomic status, which may in part relate to higher prevalence of
HS risk factors in this group, or could be a consequence of
HS.7
Environmental associations
Smoking and obesity are the two environmental factors most
strongly linked to HS (Table 2). A systematic review including
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6174 HS cases and 24 993 controls demonstrated an odds
ratio (OR) of 434 (95% CI 248–760) for HS and current
smoking and an OR of 345 (95% CI 220–538) for HS and
obesity.18 Both higher smoking pack-years and higher body
mass index (BMI) have been linked to greater disease sever-
ity.19 In multivariate analysis, an increase in one unit of BMI
was associated with an increase of 084 units in mean Sarto-
rius HS severity score.20 It should be noted that there is a rela-
tive lack of prospective longitudinal cohort data to confirm
whether smoking and obesity are true risk factors for HS
initiation.
Association with other medical conditions
Follicular occlusion
A link between HS and pilonidal sinus is expected because
both are characterized by follicular occlusion. Case–control
studies demonstrate five-fold higher odds of pilonidal sinus in
those with HS compared with controls,8,11 one of the stron-
gest associations between HS and other medical conditions
(Table 3). It is likely that pilonidal sinus is part of the HS dis-
ease spectrum.21
Table 1 Methodology, population and data sources used for hidradenitis suppurativa prevalence estimate in North America and Europea
Methodology Population Data source
Prevalence estimate,
% (95% CI)
Reference
(first author, year)
Population-based,
diagnostic codes
Diagnosed cases from 15
million individuals in
the USA
Insurance claims Period prevalence in 2007:
0053 (0051–0054)
Cosmatos 20135
Population-based,
diagnostic code
Diagnosed cases from 48
million individuals in
the USA
Insurance claims and self-pay
records
010 (0097–0099) Garg 201710
Population-based,
diagnostic codes
Diagnosed cases from
144 000 individuals in
Olmsted County, USA
Rochester Epidemiology
Project, centralized database
for most healthcare
providers
013 (011–015) Shahi 201458
Population-based,
diagnostic code and
algorithm for multiple
flexural skin boils
Diagnosed and
undiagnosed cases from
43 million individuals
in the UK
Routinely collected primary
care CPRD database
077 (076–078)
Including probable cases:
119 (118–120)
Ingram 20188
Cross-sectional study:
positive responses to
survey question about
painful flexural boils
10 000 members of the
general French
population
6887 questionnaire responses
in those aged 15 years or
older
Period prevalence in previous
12 months: 097
Revuz 200815
Cross-sectional study:
positive responses to
two survey questions
about skin boils
Members of the general
Danish population
16 404 questionnaire
responses (49% response
rate) in those aged 30 years
or older
210 (188–232) Vinding 201459
In-person examination by
dermatologists
507 patients, male-to-
female ratio 12 : 1,
mean age 27 years,
undergoing screening
for sexually transmitted
diseases
History and examination
findings
41 (30–60) Jemec 19966
aReferences are examples, rather than an exhaustive list. CI, confidence interval; CPRD, Clinical Practice Research Datalink.
Table 2 Environmental risk factors/associations from European and North American hidradenitis suppurativa case–control studiesa
Reference (first author, year)
Odds ratio (95% CI)
Current smoker Past smoker Obesityb
Revuz 200815,c 1255 (858–1838) 146 (086–246) 442 (282–693)
Shlyankevich 201437 209 (103–422)
Ingram 20188 361 (344–379) 193 (181–205) 329 (314–345)
Shalom 201560 174 (156–194)
Miller 201461,d 258 (200–323)
aReferences are examples, rather than an exhaustive list; bobesity is defined as a body mass index greater than 30; cmedically assessed patients
(n = 302); dpopulation-level data shown (n = 326). CI, confidence interval.
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Acne conglobata is strongly associated with HS in Korean
patients (prevalence 45%; OR 507, 95% CI 469–549)11
and the association remains relatively strong between HS and
acne vulgaris in UK patients (OR 177, 95% CI 166–188).8
Metabolic syndrome
Metabolic syndrome is typically defined by at least three of:
abdominal obesity, dyslipidaemia, hypertension and diabetes
mellitus. Regarding dyslipidaemia, a systematic review of
case–control studies found associations between HS and
hypertriglyceridaemia (pooled OR 167, 95% CI 114–247)
and low high density lipoprotein (OR 248, 95% CI 149–
416).18 Meta-analysis investigating a possible association
between HS and type 2 diabetes gave a pooled OR of 285
(95% CI 134–608)18 and a subsequent review of a subset of
adjusted analyses gave a pooled OR of 169 (95% CI 150–
191).22 While several individual case–control studies have
demonstrated a statistically significant association between HS
and hypertension, meta-analysis of the data available in 2015
gave a nonsignificant result in the context of a relatively wide
95% CI (OR 15, 95% CI 063–358).18 Nevertheless, adding
in the strong association between HS and obesity, there is a
40% prevalence of metabolic syndrome in people with HS.23
Meta-analysis of available studies confirmed an OR of 222
(95% CI 162–306) for metabolic syndrome in HS compared
with controls.18 Insulin resistance is also increased in HS, pre-
sent in 43% of those with HS compared with 16% of con-
trols.24
Cardiovascular disease
Does the higher prevalence of cardiovascular disease (CVD)
risk factors including smoking and metabolic syndrome in
people with HS translate into higher rates of CVD and CVD-re-
lated mortality? The answer was provided in 2016 by a popu-
lation-based cohort study using Danish nationwide
administrative registers.25 Overall, 5964 patients with a hospi-
tal-confirmed diagnosis of HS were matched with 29 404
controls. The adjusted incidence rate ratio (IRR) was 157
(95% CI 114–217) for myocardial infarction and 133 (95%
CI 101–176) for ischaemic stroke. The adjusted IRR for
CVD-associated mortality was 195 (95% CI 142–267).
When patients with severe psoriasis were used as the control
group, the adjusted IRR for CVD-associated mortality remained
significantly higher in the HS cohort (IRR 158, 95% CI 117–
212). Death from CVD is the largest component of higher
all-cause mortality in HS. A Finnish registry study found mean
age at death was 605 years in people with HS, compared
with 711 years in psoriasis and 752 years in naevi con-
trols.26
Chronic inflammatory diseases
In European and North American populations, case–control
studies demonstrate a strong association between HS and Ta
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Crohn disease, independent of their mutual association with
smoking. Prevalence of Crohn disease was 2% in patients with
HS in the USA, compared with 06% in controls, and multi-
variable analysis demonstrated that patients with HS had 305
(95% CI 287–325) times the odds of having Crohn disease
compared with those without HS.27 The prevalence of Crohn
disease in European patients was even higher at 25%.28 How-
ever, there was no association between HS and Crohn disease
in Korean patients.11
Data from four studies conducted in Denmark,29 the UK,8
Israel30 and South Korea11 were included in a meta-analysis
investigating the occurrence of ulcerative colitis in patients
with HS.31 In this case there was an association between HS
and ulcerative colitis in Korean patients and the pooled OR
was 151 (95% CI 125–182).
Data regarding any association between HS and psoriasis are
somewhat conflicting. A study from the UK found no associa-
tion,8 whereas studies from South Korea and Denmark found
strong associations with ORs of 458 (95% CI 421–497) and
299 (95% CI 204–438), respectively.11,32 It should be
noted that biological therapy is associated with paradoxical
development of HS in a few patients with psoriasis and para-
doxical psoriasis in a minority of patients with HS.33
In South Korean patients, an association was demonstrated
between HS and ankylosing spondylitis (OR 147, 95% CI
114–189) and rheumatoid arthritis (OR 131, 95% CI 116–
147).11 Among commercially insured patients in the USA,
longitudinal claims data showed that patients with HS had an
increased risk of developing ankylosing spondylitis compared
with those without HS [hazard ratio (HR) 165, 95% CI
115–235].34 There were also modest but significant associa-
tions with development of psoriatic arthritis (HR 144, 95%
CI 108–193) and rheumatoid arthritis (HR 116, 95% CI
103–131).
Mental health
In keeping with HS being a socially isolating, painful chronic
condition, a systematic review and meta-analysis revealed a
high prevalence of depression, 21%, in those with HS.35 An
analysis of nine case–control studies gave an OR for the asso-
ciation between HS and depression of 199 (95% CI 163–
243). There was a similar association between HS and anxi-
ety, with a prevalence of 12% and a pooled OR of 197 (95%
CI 165–235).
Perhaps in part secondary to increased mental health prob-
lems, a higher risk of completed suicide was found in a retro-
spective cohort study using Danish national registry data
adjusted for confounding factors.36 The HR for completed sui-
cide in patients with HS compared with those without HS was
242 (95% CI 107–545).
Other medical conditions
There is considerable overlap between the demographics of
HS and polycystic ovary syndrome (PCOS) and anti-androgen
therapy can be helpful in both conditions. Is there an associa-
tion between the two conditions? Nearly all case–control stud-
ies confirm an association, with a very high OR of 137 (95%
CI 400–473) in one study from the USA37 and an OR of
214 (95% CI 204–224) in another, which found a preva-
lence of 90% for PCOS in those with HS.38 A study from the
UK did not find an association. While there was a slightly
higher prevalence of PCOS in people with HS compared with
controls, statistical significance was not reached (OR 119,
95% CI 096–149).8
An association between HS and Down syndrome was
demonstrated by a cross-sectional analysis of electronic medi-
cal records of 48 million individuals in the USA.39 The
adjusted odds of HS in people with Down syndrome was 524
(95% CI 462–594) times the odds in those without Down
syndrome. The diagnosis of HS was made by the age of
29 years in 82% of people with Down syndrome compared
with only 34% of people without Down syndrome. It may be
that HS occurs at a younger age in those with Down syn-
drome or that age of onset is unaffected and instead there is
earlier recognition of HS.
In the context that obesity is associated with both HS and
obstructive sleep apnoea (OSA), it is intuitively likely that HS
is linked to OSA. An association was confirmed in routinely
collected healthcare data with an OSA prevalence of 35% in
those with HS and an OR compared with controls of 145
(95% CI 133–157).40
Transformation of the chronic inflammation of HS into
cutaneous squamous cell carcinoma (cSCC) is rare and so the
literature is limited to case reports and small case series. A
review of the literature in 2016 identified a total of 80
cases.41 Most cases were in men (87%) and the average age at
diagnosis was 52 years. Nearly all patients (95%) had involve-
ment of the perianal, perineal or buttock regions. Patients
often presented late, with 55% having metastases at initial pre-
sentation, probably due to a combination of cSCC being diffi-
cult to distinguish clinically from HS and the potential for
contiguous spread via HS skin tunnels.
Pyoderma gangrenosum (PG) shares some of the clinical
and epidemiological features of HS and both conditions are
components of several autoinflammatory syndromes. Multi-
variable analysis of routinely collected USA healthcare data
demonstrated that the odds of someone with HS having con-
comitant PG were 211 (95% CI 175–255) times the odds in
the absence of HS.42 The prevalence of PG was substantially
higher in those with HS and Crohn disease compared with
those with HS alone, 368% compared with 012%, respec-
tively. When patients with Crohn disease were excluded from
the analysis, those with HS were still much more likely to
have PG than those without HS (OR 265, 95% CI 211–
334), which suggests that the association between HS and PG
is independent of Crohn disease status.
Some of the association between HS and PG is accounted
for by the autoinflammatory syndromes PASH (PG, acne con-
globata and HS), PAPASH (pyogenic arthritis, acne, PG and
HS) and PASS (PG, acne vulgaris, HS and ankylosing
© 2020 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2020)
Epidemiology of HS, J.R. Ingram 5
spondylitis).43 While the epidemiology of these syndromes
has not been fully described, the literature is limited to case
reports and small case series and so the syndromes are proba-
bly relatively rare and their contribution to the overall associa-
tion between HS and PG is likely to be small.
A meta-analysis of case–control studies investigating thyroid
disorders in patients with HS demonstrated an OR of 188
(95% CI 125–281) in favour of an association.44 After
adjustment for age, sex, BMI and oral contraception in one of
the case–control studies, the associations between HS and sub-
clinical hyperthyroidism and clinical hyperthyroidism
remained significant, whereas there was no association with
hypothyroidism.45 The clinical significance of the association
between HS and hyperthyroidism is attenuated by relatively
low absolute increases in prevalence.
Renal amyloidosis is a potential issue secondary to the
inflammatory load of HS. Renal function was compared
between Danish control individuals, 32 patients with HS in
secondary care and 430 people with HS identified by responses
to the Danish General Suburban Population Study (GESUS)
questionnaire.46 After adjusting for confounders, there was no
difference in estimated glomerular filtration rate (eGFR)
between individuals with HS in the population and controls
but there was a higher eGFR in patients with HS in secondary
care compared with controls, the mean difference being
681 mL min–1 173 m–2 (95% CI 127–1235 mL min–1
173 m–2). The results suggest that while most people with HS
do not have renal dysfunction, there may be an association
between more severe HS and a degree of glomerular hyperfil-
tration, a marker of potential renal dysfunction.
In a parallel study to the investigation of eGFR, haemoglo-
bin (Hb) levels were examined to look for any association
between HS and anaemia, in the context that people with HS
frequently report fatigue. Unadjusted and adjusted analysis
demonstrated no difference in Hb levels or rates of anaemia
between Danish controls and individuals with HS in the popu-
lation or the hospital HS group.47 In contrast, a case–control
study of 1431 patients with HS in the USA compared with a
control group of 8518 patients with acne vulgaris did find an
association between HS and anaemia.48 The OR for anaemia
in patients with HS compared with patients with acne after
controlling for BMI and HbA1C was 220 (95% CI 142–341).
The association was particularly strong in male patients with
an OR of 561 (95% CI 186–1690). There was a dose–re-
sponse effect observed in males, with the odds of moder-
ate/severe anaemia, defined as Hb equal to or less than 110 g
dL–1, being 907 (95% CI 198–4143) times higher in
patients with HS compared with patients with acne.
Discovery that loss-of-function mutations in c-secretase
genes cause HS in some Han Chinese patients49 led to a search
for a possible association between HS and Alzheimer disease,
on the basis that familial Alzheimer disease is caused by c-sec-
retase missense mutations.50 However, there is no current
support for a link between HS and Alzheimer disease, with
several case–control studies finding no association.8,51,52
Hepatic ultrasonography was used to show a 729% preva-
lence of nonalcoholic fatty liver disease in patients with HS
compared with 247% in age- and sex-matched controls and
after adjustment for classic metabolic risk factors, the OR was
775 (CI 25–236).53
Figure 1 Summary of the epidemiology of hidradenitis suppurativa (HS). CVD, cardiovascular disease; IBD, inflammatory bowel disease; PCOS,
polycystic ovary syndrome; cSCC, cutaneous squamous cell carcinoma.
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Hidradenitis suppurativa phenotypic subtypes
Our understanding of the epidemiology of HS is likely to
evolve as we begin to recognize HS phenotypic subtypes. Dif-
ferences are already apparent in the male-to-female ratio for
HS in European compared with Asian populations. There have
been several attempts to identify HS subphenotypes, including
latent class analysis which divided patients into three classes:
(i) predominantly axillary and chest involvement mainly
affecting women; (ii) a follicular subtype associated with sev-
ere acne mainly affecting men; and (iii) a gluteal form with
predominantly buttock involvement.54,55
Natural history
Investigation of the natural history of HS is limited by a rela-
tive lack of prospective cohort studies. A retrospective analysis
of 846 patients with HS from the Netherlands identified five
severity risk factors, namely male sex, obesity, smoking pack-
years, disease duration and lesions in the axillary, perianal and
mammary regions.19 Positive family history was linked to ear-
lier disease onset but not to more severe disease.
A cross-sectional postal questionnaire study assessed risk
factors, clinical course and prognosis in 141 Danish patients
with HS and 79 Dutch patients with HS under follow-up for a
median of 22 years.56 From the 129 fully completed
responses, rates of remission, improvement, unchanged sever-
ity and worsening were 39%, 32%, 21% and 8%, respectively.
Current nonsmokers were more likely to report remission than
active smokers (40% vs. 29%) and a higher proportion of
nonobese patients (45%) reported remission compared with
obese patients (23%).
A further cross-sectional survey of female patients with HS
in the Netherlands investigated the influence of menses and
pregnancy on disease severity.57 Of the 186 respondents, 43%
reported a deterioration of HS at the time of menses, while
54% reported no change. Pregnancy was associated with HS
improvement, no change, or worsening in 30%, 53% and
17%, respectively. Improvement during pregnancy correlated
with worsening at the time of menses.
Disease onset at or soon after puberty is supported by the
peak in new HS diagnoses occurring in those aged 18–29 years,
factoring in an average delay in diagnosis of 7 years.2,14 It has
been suggested that there could be correspondingly higher rates
of remission in women reaching menopause. In support of this
theory, the female-to-male ratio alters from 5 : 1 for the age
range 20–29 years to 3 : 1 for those aged 50–59 years.8 How-
ever, prospective data are not yet available.
Conclusion
Our understanding of the epidemiology of HS has greatly
increased in the last decade. The use of routinely collected
healthcare data has permitted population-based studies of
prevalence and incidence and case–control studies have
established multiple associations between HS and other medi-
cal conditions, in particular CVD, inflammatory bowel disease
and depression (Figure 1). Mortality rates from CVD are more
than 50% higher in HS than in psoriasis and there is an
increased risk of completed suicide compared with controls.
Smoking and obesity are closely associated with HS and may
also increase disease severity.
Several unanswered questions remain. What is the true
prevalence of HS in Europe and North America, when preva-
lence figures vary by an order of magnitude? What is the nat-
ural history of HS, particularly regarding predictors of disease
trajectory? In addition, is the epidemiology of HS uniform
across different phenotypic subclasses and across populations
with differing ethnicity? There is still a lot of work to be
done.
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